There are currently 2869 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Parenting Support Intervention for Families Coping with Metastatic or Locally Recurrent Solid Tumor Diagnosis
NCT05059678
Recruiting
This clinical trial examines the acceptability and effect of a parenting support intervention for families coping with solid tumor that has spread to other places in the body (metastatic) or has come back (recurrent). Parenting support program may help to reduce common parenting concerns, improve communication between parents and children about cancer, and improve the overall psychological wellbeing of parents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Register for Updates
Freedom-1 Study for Chronic Knee Pain
NCT03877653
Recruiting
To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Performance pain and sports medicine, Houston, Texas
Conditions: Osteoarthritic Knee Pain
Register for Updates
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
NCT06271512
Recruiting
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
Gender:
ALL
Ages:
All
Trial Updated:
02/10/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Beta-Thalassemia
Register for Updates
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
NCT06162377
Recruiting
To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
NCT06466798
Recruiting
The goal of this clinical trial is to assess the safety, toxicity, and antitumor activity of fourth ventricular infusions of nivolumab plus 5-azacytidine for recurrent ependymoma and nivolumab plus methotrexate for recurrent medulloblastoma and other CNS malignancies. Additionally, the study will explore immunologic responses to nivolumab. The hypothesis is that local administration of nivolumab, an immune checkpoint inhibitor, is safe and will lead to even more robust treatment responses when... Read More
Gender:
ALL
Ages:
Between 1 year and 80 years
Trial Updated:
02/10/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Recurrent Ependymoma, Recurrent Medulloblastoma, CNS Malignancies
Register for Updates
A Study of BION-1301 in Adults With IgA Nephropathy
NCT05852938
Recruiting
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: University of Texas MD Anderson Cancer Center-1155 Pressler, Houston, Texas
Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Register for Updates
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
NCT04380545
Recruiting
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as fluorouracil, work in different ways to stop the growth of tumo... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/10/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Fibrolamellar Carcinoma
Register for Updates
Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788
Recruiting
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Register for Updates
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
NCT03833921
Recruiting
The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason for the study is that researchers think that there may be a connection between the race and ethnicity of men with prostate cancer and how well the standard treatments work for the participants.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Ben Taub General Hospital, Houston, Texas +2 locations
Conditions: Prostate Cancer Metastatic, Prostate Cancer
Register for Updates
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
NCT06492304
Recruiting
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/10/2025
Locations: Research Site 1, Houston, Texas
Conditions: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Register for Updates
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
NCT06821100
Recruiting
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections. This research study will test the safety and possible harms of Ta1 when it is given to people at different dose levels before COVID-19 vaccination.
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
02/10/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
Register for Updates
A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
NCT05193929
Recruiting
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Mt. Olympus Medical Research, Houston, Texas +1 locations
Conditions: Diabetic Foot Ulcer
Register for Updates